Rapid Diagnostic Test Kits Global Market Report 2025

The rapid diagnostic test kits market size has grown strongly in recent years. It will grow from $22.66 billion in 2024 to $24.08 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The historical growth was driven by the increasing incidence of infectious diseases, growing popularity of point-of-care diagnostics, heightened demand for early detection during health crises, enhanced government investments in controlling infectious diseases, and broader adoption of rapid tests in underserved and rural regions.

The rapid diagnostic test kits market size is expected to see strong growth in the next few years. It will grow to $30.44 billion in 2029 at a compound annual growth rate (CAGR) of 6%. This future growth will be supported by increased use of at-home diagnostic solutions, rising healthcare investments in emerging markets, growing preference for rapid disease detection, enhanced backing from international health agencies, and a shift toward decentralized models of healthcare. Key trends expected in the market include innovations in microfluidic diagnostic systems, smartphone-compatible testing tools, the rise of multi-target rapid testing kits, advancements in personalized testing methods, and growing investment in diagnostic innovation and R&D.

The increasing focus on point-of-care and at-home testing is anticipated to drive the growth of the rapid diagnostic test kits market in the coming years. These types of testing refer to diagnostic procedures conducted outside traditional laboratory settings, either directly at the site of patient care or within the home, offering quick and convenient results that facilitate timely medical decisions. The demand for point-of-care and at-home testing is rising as individuals seek faster and more convenient health assessments that eliminate the need for laboratory visits, reduce wait times, and support health management from the comfort of their homes. Rapid diagnostic test kits complement these needs by providing quick, reliable results without requiring specialized equipment, thus enabling timely decisions outside conventional labs. For example, in August 2022, the Centers for Disease Control and Prevention reported that during 2021-2022, 10.7 million at-home COVID-19 test results were voluntarily submitted in the United States, underscoring the shift toward self-testing over traditional methods. As a result, the growing focus on point-of-care and at-home testing is contributing significantly to the expansion of the rapid diagnostic test kits market.

Companies in the rapid diagnostic test kits market are increasingly investing in innovative solutions such as saliva-based pregnancy test kits to maintain a competitive advantage. These kits are designed to detect pregnancy by identifying hormonal changes, particularly human chorionic gonadotropin (hCG), in a woman's saliva. For instance, in February 2023, Abingdon Health plc, a diagnostics company based in the UK, introduced Salistick, the first rapid saliva-based pregnancy test in the UK and Ireland. This product represents a notable advancement in home pregnancy testing by offering a cleaner and more user-friendly alternative to traditional urine-based methods. The highly accurate test allows women to detect pregnancy at an early stage using saliva, enabling testing to be conducted anytime and anywhere, and offering a more discreet and shareable experience.

In June 2023, Avacta Group, a biotechnology firm headquartered in the UK, completed the acquisition of Coris Bioconcept SRL for $8.42 million. This acquisition is intended to enhance Avacta’s diagnostics portfolio by incorporating Coris’s range of rapid test products and expertise. The move strengthens Avacta’s capabilities in both centralized laboratory diagnostics and decentralized point-of-care testing, reinforcing its presence in the growing sectors of infectious disease and antimicrobial resistance diagnostics. Coris Bioconcept SRL, based in Belgium, develops and supplies rapid diagnostic kits for identifying respiratory, gastrointestinal, and blood-borne pathogens in humans.

Major players in the rapid diagnostic test kits market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Cepheid Inc., OraSure Technologies Inc., Nova Biomedical Corporation, Sekisui Diagnostics LLC, EKF Diagnostics Holdings plc, Trinity Biotech plc, ACON Laboratories Inc., Fluxergy LLC, Lumos Diagnostics Holdings Limited, Abingdon Health plc, and Abionic SA.

North America was the largest region in the rapid diagnostic test kits market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rapid diagnostic test kits report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rapid diagnostic test kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Rapid diagnostic test kits are portable, user-friendly medical devices designed to swiftly identify the presence or absence of particular diseases, infections, or medical conditions. These kits often provide results within minutes, making them essential for point-of-care testing, early detection, and prompt treatment decisions in both clinical and remote environments.

The primary product categories of rapid diagnostic test kits include antigen test kits, antibody test kits, nucleic acid test kits, and multi-analyte test kits. Antigen test kits function by detecting specific proteins from pathogens, such as viruses, to promptly confirm active infections. These kits are segmented by technology into fluorescent immunoassay, enzyme-linked immunosorbent assay, colloidal gold-based test, and lateral flow assays. They are also classified by application areas, such as infectious disease testing, cardiology testing, oncology testing, pregnancy and fertility testing, toxicology testing, glucose monitoring, and others. The key end-users of these kits include hospitals, diagnostic laboratories, home care settings, and pharmacies.

The rapid diagnostic test kits market research report is one of a series of new reports that provides rapid diagnostic test kits market statistics, including the rapid diagnostic test kits industry global market size, regional shares, competitors with the rapid diagnostic test kits market share, detailed rapid diagnostic test kits market segments, market trends, and opportunities, and any further data you may need to thrive in the rapid diagnostic test kits industry. This rapid diagnostic test kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rapid diagnostic test kits market consists of sales of influenza test kits, malaria test kits, pregnancy test kits, glucose monitoring kits, hepatitis test kits, and dengue test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.